e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail: e - mail:riociguat Hossein-Ardeschir % T的影响持久/复发患者慢性血栓栓塞肺动脉高压(CTEPH)后肺动脉内膜切除术(豌豆)% D J欧洲呼吸杂志2014% % P V 44% 3421% N 5 58% X BackgroundPEA推荐治疗CTEPH大多数会有疗效病人(pts)。然而，有些患者在PEA后存在持续性/复发性肺动脉高压(PH)。目的胸部研究的亚组分析评估了利ociguat对PEA术后持续/复发性PH患者的长期影响。方法在CHEST-1中，72例PEA术后持续/复发性PH患者被随机分为利ociguat (2.5 mg tid)或安慰剂(pbo)治疗16周。在完成CHEST-1后，符合条件的患者可以进入长期扩展研究CHEST-2，所有患者均接受riociguat治疗。报告了中期分析(2013年3月审查)的结果。结果与pbo相比，riociguat组的chest - 1,6mwd和几个次要终点均有改善。在CHEST-1的PEA术后72例持续/复发性PH患者中，65例进入了CHEST-2(平均年龄58±15岁，自PEA以来平均时间3.3年)。 At censor date, 86% (n=56) of pts were ongoing, 69% (n=45) attended the 1-yr visit, and 14% (n=9) had discontinued, of whom 8% (n=5) had died. Riociguat was well tolerated; 2% (n=1) of pts withdrew due to adverse events. Improvements in 6MWD at Wk 12 of CHEST-2 vs CHEST-1 baseline (ex-riociguat 40±75 m; ex-pbo 44±43 m) were sustained for 1 yr in the overall cohort (44±64 m; n=42). WHO functional class improved/stabilized/worsened in 42/53/4% and 42/58/0% of the ex-riociguat and ex-pbo pts, respectively, at Wk 12 of CHEST-2, and 49/51/0% of pts at 1 yr (n=43).ConclusionsLong-term riociguat was well tolerated in pts with persistent/recurrent PH following PEA and improved 6MWD and secondary endpoints for up to 1 yr. %U